Biomarkers in Hepatocellular Carcinoma

Biomarkers in Hepatocellular Carcinoma: Comprehensive Lecture Summary

1. Main Clinical Topics Discussed

• Current limitations of existing surveillance tools for hepatocellular carcinoma (HCC)
• Development and validation of novel protein-based tissue and serum biomarkers for early HCC detection
• Multi-institutional consortium approach to biomarker discovery and validation
• Application of artificial intelligence (AI) and machine learning to immunohistochemical (IHC) analysis
• The TGF-β signaling pathway as a foundational framework for HCC biomarker research

2. Key Learning Points, Guidelines, and Recommendations

Limitations of Current HCC Surveillance:

• Ultrasound surveillance has limited sensitivity, further reduced in patients with obesity and NAFLD/NASH (now affecting approximately one-third of the at-risk population)
• Poor patient compliance with scheduled ultrasound surveillance
• Alpha-fetoprotein (AFP) is not elevated in up to one-third of HCC cases
• AFP has limited utility as an independent prognostic biomarker outside of longitudinal study settings

Biomarkers in Advanced Phase Trials (Phase 3–4):

• Highly reactive AFP-L3
• Des-gamma-carboxy prothrombin (DCP/PIVKA-II)
• Midkine
• Glypican-3
• Osteopontin
• Acetyl nitrite
• MicroRNAs, DNA methylation markers, proteomic analyses of tissue interstitial fluid, and extracellular vesicles

Key Challenges Identified:

• HCC is biologically heterogeneous with multiple etiologies and divergent pathophysiology
• Proteomics historically underutilized due to limited access and high cost of antibodies
• Geographic and resource disparities limit widespread applicability of complex biomarker assays

The Speaker's Strategic Approach — 10 Functional Biological Biomarkers:

• TGF-β Type 1 and Type 2 receptors
• R-spondin 3
• Sema4C (TGF-β adapter protein)
• Inter-alpha-trypsin inhibitor heavy chain (ITIH4)
• HMGA2 (High Mobility Group A2)
• EpCAM (epithelial cell adhesion molecule — stem cell marker)
• Polo-like kinase (PLK)
• Sirtuin 6 (SIRT6)
• FANCD2 (Fanconi anemia complementation group D2 — DNA repair pathway)

Proposed Clinical Pathway:

• Identify at-risk patients → longitudinal follow-up → molecular characterization → risk stratification → targeted or less invasive treatment for high-risk individuals

3. Specific Clinical Data, Statistics, and Study Results Cited

Consortium Structure (NCI-funded U01):

• Three independent cohorts: George Washington University (GW1), University of Hawaii (GW2), University of Maryland (GW3)
• Collaboration also included MD Anderson Cancer Center and NCI intramural investigators
• Standardized operating protocols, cross-institutional sample sharing, and MTA agreements established
• Two independent pathologists analyzed each sample with cross-institutional reproducibility testing

Key Immunohistochemical Findings:

• TGF-β Type 2 receptor: Consistently and significantly decreased in HCC compared to cirrhotic liver; finding reproducible across all three institutions using multivariate logistic regression (Kowalski test)
• TGF-β Type 1 receptor: Decreased in HCC in at least one cohort (notably the Hawaii/Asian-ancestry population); less consistent across institutions
• EpCAM: Strongly positive in portal tract progenitor-like cells in adjacent/cirrhotic liver; diffusely and aberrantly expressed in HCC
• Polo-like kinase: Elevated in HCC vs. cirrhosis; notably relevant in Asian HCC patients with hepatitis B and liver fluke infection
• HMGA2: Elevated in HCC compared to normal and cirrhotic liver
• R-spondin 3: Elevated in adjacent cirrhotic tissue but absent/markedly reduced in HCC
• SIRT6, ITIH4, Sema4C, FANCD2: Variable/inconsistent expression patterns —